UB Paderborn / Katalog / Suche / in CDI

Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial

Clinical cancer research, 2017-07, Vol.23 (13), p.3277-3284

2017

Link zum Volltext

Verfügbarkeit prüfen

Phase Ia dose escalation study of OBP-801, a cyclic depsipeptide class I histone deacetylase inhibitor, in patients with advanced solid tumors

Investigational new drugs, 2022-04, Vol.40 (2), p.300-307

2022

Link zum Volltext

Verfügbarkeit prüfen

How Sociodemographics, Presence of Oncology Specialists, and Hospital Cancer Programs Affect Accrual to Cancer Treatment Trials

Journal of clinical oncology, 2002-04, Vol.20 (8), p.2109-2117

2002

Link zum Volltext

Verfügbarkeit prüfen

Assessing Whether to Perform a Confirmatory Randomized Clinical Trial

JNCI : Journal of the National Cancer Institute, 1996-11, Vol.88 (22), p.1645-1651

1996

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and genetic analysis for a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic immunotherapy, and ipilimumab combination treatment in patients with stage IIIb-IV unresectable or metastatic melanoma

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.9541-9541

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract C111: Safety profile and tumor response in patients with refractory superficial cancers treated with HF10, an oncolytic replication-competent HSV-1-derived intratumoral injectable, as monotherapy and combined with ipilimumab

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.C111-C111

2015

Link zum Volltext

Verfügbarkeit prüfen

Final results of a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.9510-9510

2017

Link zum Volltext

Verfügbarkeit prüfen

Preliminary results from phase II study of combination treatment with HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab in patients with stage IIIb, IIIc, or IV unresectable or metastatic melanoma

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.9543-9543

2016

Link zum Volltext

Verfügbarkeit prüfen

Report of the Cancer Therapy Evaluation Program Monitoring Plan for Secondary Acute Myeloid Leukemia Following Treatment With Epipodophyllotoxins

JNCI : Journal of the National Cancer Institute, 1993-04, Vol.85 (7), p.554-558

1993

Link zum Volltext

Verfügbarkeit prüfen

Phase I trial of intratumoral therapy using HF10, an oncolytic HSV-1, demonstrates safety in HSV+/HSV- patients with refractory and superficial cancers

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.6082-6082

2014

Link zum Volltext

Verfügbarkeit prüfen

Representation of older patients in cancer treatment trials

Cancer, 1994-10, Vol.74 (S7), p.2208-2214

1994

Link zum Volltext

Verfügbarkeit prüfen

A phase I trial of intratumoral administration of HF10 in patients with refractory superficial cancer: Immune correlates of virus injection

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.3099-3099

2013

Link zum Volltext

Verfügbarkeit prüfen

Representation of African-Americans, Hispanics, and Whites in National Cancer Institute Cancer Treatment Trials

JNCI : Journal of the National Cancer Institute, 1996-06, Vol.88 (12), p.812-816

1996

Link zum Volltext

Verfügbarkeit prüfen

Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4'-(9-acridinylamino)methanesulfon-m-anisidide and adriamycin

Biochemistry (Easton), 1981-11, Vol.20 (23), p.6553-6563

1981

Link zum Volltext

Verfügbarkeit prüfen

National cancer clinical trials: Children have equal access; adolescents do not

Journal of adolescent health, 1997-12, Vol.21 (6), p.366-373

1997

Link zum Volltext

Verfügbarkeit prüfen

Dose Intensity of Chemotherapy for Childhood Cancers

The oncologist (Dayton, Ohio), 1996-10, Vol.1 (5), p.293-304

1996

Link zum Volltext

Verfügbarkeit prüfen

Influence of Doxorubicin Dose Intensity on Response and Outcome for Patients With Osteogenic Sarcoma and Ewing's Sarcoma

JNCI : Journal of the National Cancer Institute, 1991-10, Vol.83 (20), p.1460-1470

1991

Link zum Volltext

Verfügbarkeit prüfen

Conduct of phase I trials in children with cancer

Journal of clinical oncology, 1998-03, Vol.16 (3), p.966-978

1998

Link zum Volltext

Verfügbarkeit prüfen

Role of independent data-monitoring committees in randomized clinical trials sponsored by the National Cancer Institute

Journal of clinical oncology, 1997-07, Vol.15 (7), p.2736-2743

1997

Link zum Volltext

Verfügbarkeit prüfen

Equal participation of minority patients in U.S. national pediatric cancer clinical trials

Journal of pediatric hematology/oncology, 1997-09, Vol.19 (5), p.423-427

1997

Link zum Volltext

Verfügbarkeit prüfen

Children and cancer. A perspective from the cancer therapy evaluation program, national cancer institute

Cancer, 1993-05, Vol.71 (S10), p.3422-3428

1993

Link zum Volltext

Verfügbarkeit prüfen

Secrecy for data monitoring committees: inferior ethics, bad policy

Journal of clinical oncology, 1998-01, Vol.16 (1), p.390-391

Wells, R J

1998

Link zum Volltext

Verfügbarkeit prüfen

A comparison of four staging systems for localized and regional neuroblastoma: a report from the Childrens Cancer Study Group

Journal of clinical oncology, 1990-04, Vol.8 (4), p.678-688

1990

Link zum Volltext

Verfügbarkeit prüfen

Sex, Trials, and Datatapes

JNCI : Journal of the National Cancer Institute, 1991-01, Vol.83 (1), p.16-17

1991

Link zum Volltext

Verfügbarkeit prüfen

Response

JNCI : Journal of the National Cancer Institute, 1992-02, Vol.84 (3), p.203-204

1992

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial

Phase Ia dose escalation study of OBP-801, a cyclic depsipeptide class I histone deacetylase inhibitor, in patients with advanced solid tumors

How Sociodemographics, Presence of Oncology Specialists, and Hospital Cancer Programs Affect Accrual to Cancer Treatment Trials

Assessing Whether to Perform a Confirmatory Randomized Clinical Trial

Efficacy and genetic analysis for a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic immunotherapy, and ipilimumab combination treatment in patients with stage IIIb-IV unresectable or metastatic melanoma

Abstract C111: Safety profile and tumor response in patients with refractory superficial cancers treated with HF10, an oncolytic replication-competent HSV-1-derived intratumoral injectable, as monotherapy and combined with ipilimumab

Final results of a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma

Preliminary results from phase II study of combination treatment with HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab in patients with stage IIIb, IIIc, or IV unresectable or metastatic melanoma

Report of the Cancer Therapy Evaluation Program Monitoring Plan for Secondary Acute Myeloid Leukemia Following Treatment With Epipodophyllotoxins

Phase I trial of intratumoral therapy using HF10, an oncolytic HSV-1, demonstrates safety in HSV+/HSV- patients with refractory and superficial cancers

Representation of older patients in cancer treatment trials

A phase I trial of intratumoral administration of HF10 in patients with refractory superficial cancer: Immune correlates of virus injection

Representation of African-Americans, Hispanics, and Whites in National Cancer Institute Cancer Treatment Trials

Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4'-(9-acridinylamino)methanesulfon-m-anisidide and adriamycin

National cancer clinical trials: Children have equal access; adolescents do not

Dose Intensity of Chemotherapy for Childhood Cancers

Influence of Doxorubicin Dose Intensity on Response and Outcome for Patients With Osteogenic Sarcoma and Ewing's Sarcoma

Conduct of phase I trials in children with cancer

Role of independent data-monitoring committees in randomized clinical trials sponsored by the National Cancer Institute

Equal participation of minority patients in U.S. national pediatric cancer clinical trials

Children and cancer. A perspective from the cancer therapy evaluation program, national cancer institute

Secrecy for data monitoring committees: inferior ethics, bad policy

A comparison of four staging systems for localized and regional neuroblastoma: a report from the Childrens Cancer Study Group

Sex, Trials, and Datatapes

Response

Suchergebnisse filtern